Jhu et al. retrospectively analyzed patients with eGFR > 60/mL/min/year, for 5 years, with the GLP-1 RA/SGLT2i group having significantly lower risk of major adverse kidney events [31], whilst Chu et al. investigated the effectiveness of GLP-1 RA compared with basal insulin among adults treated with mainstay SGLT2i therapy for T2D and CKD. This evidence concerns the gene GLP1R and chronic kidney disease.